دورية أكاديمية
Mesenchymal stem cells decrease splenocytes apoptosis in a sepsis experimental model.
| العنوان: | Mesenchymal stem cells decrease splenocytes apoptosis in a sepsis experimental model. |
|---|---|
| المؤلفون: | Pedrazza L; Laboratório de Pesquisa em Biofísica Celular e Inflamação, Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Avenida Ipiranga 6681, prédio 12, bloco C, sala 221, Porto Alegre, Rio Grande do Sul, CEP 90619-900, Brazil., Lunardelli A, Luft C, Cruz CU, de Mesquita FC, Bitencourt S, Nunes FB, de Oliveira JR |
| المصدر: | Inflammation research : official journal of the European Histamine Research Society ... [et al.] [Inflamm Res] 2014 Sep; Vol. 63 (9), pp. 719-28. Date of Electronic Publication: 2014 Jun 03. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Birkhäuser Country of Publication: Switzerland NLM ID: 9508160 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1420-908X (Electronic) Linking ISSN: 10233830 NLM ISO Abbreviation: Inflamm Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : Birkhäuser, c1995- |
| مواضيع طبية MeSH: | Mesenchymal Stem Cell Transplantation*, Mesenchymal Stem Cells/*immunology , Sepsis/*therapy , Spleen/*cytology, Alanine Transaminase/blood ; Amylases/blood ; Animals ; Apoptosis ; Aspartate Aminotransferases/blood ; Blood Glucose/analysis ; Cells, Cultured ; Cytokines/blood ; Disease Models, Animal ; Male ; Membrane Potential, Mitochondrial ; Mice, Inbred C57BL ; Sepsis/blood ; Sepsis/immunology ; Transforming Growth Factor beta1/blood |
| مستخلص: | Objective and Design: Mesenchymal stem cells (MSCs) are potent modulators of immune responses. Sepsis is the association of a systemic inflammatory response with an infection. The aim of this study was to test the ability of MSCs derived from adipose tissue, which have immunomodulatory effects, and to inhibit the septic process in an experimental model of mice. Methods: Three experimental groups (male C57BL/6 mice) were formed for the test: control group, untreated septic group and septic group treated with MSCs (1 × 10(6) cells/animal). Results: In the control group, there were no deaths; in the untreated septic group, the mortality rate was 100 % within 26 h; in the septic group treated with MSCs, the mortality rate reached 40 % within 26 h. The group treated with MSCs was able to reduce the markers of tissue damage in the liver and pancreas. The treated group had a reduction of inflammatory markers. Furthermore, the MSCs-treated group was able to inhibit the increase of apoptosis in splenocytes observed in the untreated septic group. Conclusions: Our data showed that MSCs ameliorated the immune response with decrease of inflammatory cytokines and increase anti-inflammatory IL-10; moreover, inhibited splenocytes apoptosis and, consequently, inhibited tissue damage during sepsis. |
| References: | Cell Stem Cell. 2008 Feb 7;2(2):141-50. (PMID: 18371435) Shock. 2006 Nov;26(5):457-63. (PMID: 17047515) Crit Care Med. 2001 Jul;29(7):1303-10. (PMID: 11445675) J Surg Res. 2012 Mar;173(1):113-26. (PMID: 22225756) Crit Care. 2011;15(1):205. (PMID: 21371356) Diabetes. 2006 Apr;55(4):1096-105. (PMID: 16567534) J Nippon Med Sch. 2009 Apr;76(2):56-66. (PMID: 19443990) Exp Mol Pathol. 2000 Apr;68(2):77-84. (PMID: 10716911) Cell Transplant. 2010;19(6):667-79. (PMID: 20525442) Int Immunol. 2008 Sep;20(9):1129-38. (PMID: 18599501) Stem Cells Dev. 2010 Oct;19(10):1449-70. (PMID: 20486777) Nat Rev Immunol. 2006 Nov;6(11):813-22. (PMID: 17039247) Ann Emerg Med. 2006 Jul;48(1):28-54. (PMID: 16781920) Hepatology. 2008 May;47(5):1634-43. (PMID: 18395843) Gut. 2009 Jul;58(7):929-39. (PMID: 19136511) J Infect. 2011 Dec;63(6):407-19. (PMID: 21840338) Int J Biochem Cell Biol. 2004 Apr;36(4):568-84. (PMID: 15010324) Proc Natl Acad Sci U S A. 2003 May 27;100(11):6724-9. (PMID: 12736377) Am J Respir Cell Mol Biol. 2005 Aug;33(2):145-52. (PMID: 15891110) J Immunol. 2001 Jun 1;166(11):6952-63. (PMID: 11359857) Am J Pathol. 2004 Dec;165(6):2187-96. (PMID: 15579460) Am J Physiol Lung Cell Mol Physiol. 2012 May 15;302(10):L1003-13. (PMID: 22427530) Lancet. 2003 Aug 30;362(9385):697-703. (PMID: 12957092) Blood. 1995 Nov 15;86(10):3841-7. (PMID: 7579352) Tissue Eng. 2001 Apr;7(2):211-28. (PMID: 11304456) Am J Physiol Regul Integr Comp Physiol. 2006 Oct;291(4):R880-4. (PMID: 16728464) F1000 Med Rep. 2010 May 24;2:. (PMID: 20948844) Crit Care. 2007;11(2):R49. (PMID: 17448250) Am J Reprod Immunol. 2012 Jan;67(1):1-8. (PMID: 21951555) J Immunol. 1999 Dec 1;163(11):6148-54. (PMID: 10570305) Expert Opin Investig Drugs. 2011 Nov;20(11):1555-64. (PMID: 21961576) Crit Care Med. 2002 Sep;30(9):2069-74. (PMID: 12352043) Best Pract Res Clin Endocrinol Metab. 2001 Dec;15(4):533-51. (PMID: 11800522) Infect Immun. 2010 Apr;78(4):1582-92. (PMID: 20100863) Expert Opin Biol Ther. 2009 Oct;9(10):1259-70. (PMID: 19691441) Shock. 2002 Dec;18(6):487-94. (PMID: 12462554) Int Immunopharmacol. 2010 Dec;10(12):1496-500. (PMID: 20619384) J Cell Mol Med. 2004 Jul-Sep;8(3):301-16. (PMID: 15491506) Surgery. 2010 Aug;148(2):444-52. (PMID: 20434747) J Pediatr (Rio J). 2007 Nov;83(5 Suppl):S128-36. (PMID: 18038018) Shock. 2001 Aug;16(2):83-96. (PMID: 11508871) PLoS Med. 2007 Sep;4(9):e269. (PMID: 17803352) Nat Med. 2009 Jan;15(1):42-9. (PMID: 19098906) |
| المشرفين على المادة: | 0 (Blood Glucose) 0 (Cytokines) 0 (Transforming Growth Factor beta1) EC 2.6.1.1 (Aspartate Aminotransferases) EC 2.6.1.2 (Alanine Transaminase) EC 3.2.1.- (Amylases) |
| تواريخ الأحداث: | Date Created: 20140604 Date Completed: 20150331 Latest Revision: 20211021 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1007/s00011-014-0745-1 |
| PMID: | 24888322 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1420-908X |
|---|---|
| DOI: | 10.1007/s00011-014-0745-1 |